PT  - JOURNAL ARTICLE
AU  - ATSUO SHIDA
AU  - SHUICHI FUJIOKA
AU  - HIDEAKI KURIHARA
AU  - YOSHIO ISHIBASHI
AU  - NORIO MITSUMORI
AU  - NOBUO OMURA
AU  - KATSUHIKO YANAGA
TI  - Prognostic Significance of ZNF217 Expression in Gastric Carcinoma
DP  - 2014 Sep 01
TA  - Anticancer Research
PG  - 4813--4817
VI  - 34
IP  - 9
4099  - http://ar.iiarjournals.org/content/34/9/4813.short
4100  - http://ar.iiarjournals.org/content/34/9/4813.full
SO  - Anticancer Res2014 Sep 01; 34
AB  - Background: The zinc finger protein ZNF217 is a candidate oncogene in breast cancer and ovarian clear cell cancer. The purpose of the present study was to clarify the significance of this protein's expression in gastric carcinoma and to evaluate the outcome of these patients. Materials and Methods: Using paraffin-embedded specimens from 84 patients with gastric cancer, ZNF217 protein was detected using an anti-ZNF217 goat polyclonal antibody. We evaluated the ZNF217 protein expression in relation to patient outcome and clinicopathological parameters. Results: The ZNF217 protein was expressed in 34 (40.5%) tumor sections. Patients with ZNF217-negative tumors had better relapse-free survival (RFS) and overall survival (OS) than those with ZNF217-positive tumors by the log-rank test. Notably, multivariate analysis indicated that ZNF217 was an independent prognostic factor for RFS. Conclusion: ZNF217 expression seems to be a novel prognostic biomarker in gastric cancer.